Neufeld H N
Eur Heart J. 1986 Jul;7 Suppl B:51-2. doi: 10.1093/eurheartj/7.suppl_b.51.
SPRINT was a double-blind, randomized placebo controlled multi-centre trial based in Israel, designed to test whether nifedipine 10 mg X 3 daily would reduce morbidity and mortality during 1 year follow-up in 2279 male and female survivors of acute myocardial infarction. 335 patients were adjudged to be trial deviations. 130 (5.7%) of patients died and 105 (4.6%) experienced a non-fatal myocardial reinfarction. Analysis of the results by trial medication is awaited.
收缩压干预试验（SPRINT）是一项在以色列开展的双盲、随机、安慰剂对照的多中心试验，旨在测试每日3次服用10毫克硝苯地平是否会降低2279名急性心肌梗死男女幸存者在1年随访期内的发病率和死亡率。335名患者被判定为试验偏差。130名（5.7%）患者死亡，105名（4.6%）患者发生非致命性心肌再梗死。有待根据试验用药对结果进行分析。
